Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.06.2023 - Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical ... Seite 1
FinancialContent fully hosted finance channel
The Cleveland-based regenerative medicine company announced it has restructured its outstanding debt with a supplier that assists in the manufacturing of the MultiStem product. The deal helps advance a financial restructuring that Athersys started last year.
StockNews.com upgraded shares of Athersys (NASDAQ:ATHX – Get Rating) from a sell rating to a hold rating in a report released on Saturday morning. Separately, Alliance Global Partners assumed coverage on shares of Athersys in a report on Monday, March 6th. They set a buy rating and a $5.50 price objective for the company. Athersys […]
Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended... | May 18, 2023